Genetic data link CETP inhibition to higher AMD risk

Using drug-target Mendelian randomization and observational genetic association analyses in UK Biobank and the Singapore SEED study, researchers found that greater genetically proxied CETP inhibition was associated with increased risk of advanced and early AMD in European-ancestry participants and with exudative AMD, neovascular AMD, and polypoidal choroidal vasculopathy in East Asian-ancestry participants. The SEED cohort also showed a U-shaped association between CETP genetic score and prevalent early AMD. The authors state these findings raise a potential retinal safety signal that requires validation in clinical trials and longitudinal observational studies.

Most relevant for: Relevant to populations being considered for or treated with CETP inhibitor cardiovascular therapies, particularly those with or at risk for age-related macular degeneration.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.